139 related articles for article (PubMed ID: 9661832)
1. Immunization of common marmosets with Epstein-Barr virus (EBV) envelope glycoprotein gp340: effect on viral shedding following EBV challenge.
Cox C; Naylor BA; Mackett M; Arrand JR; Griffin BE; Wedderburn N
J Med Virol; 1998 Aug; 55(4):255-61. PubMed ID: 9661832
[TBL] [Abstract][Full Text] [Related]
2. Immunisation of common marmosets with vaccinia virus expressing Epstein-Barr virus (EBV) gp340 and challenge with EBV.
Mackett M; Cox C; Pepper SD; Lees JF; Naylor BA; Wedderburn N; Arrand JR
J Med Virol; 1996 Nov; 50(3):263-71. PubMed ID: 8923292
[TBL] [Abstract][Full Text] [Related]
3. Protective immunization against Epstein-Barr virus-induced disease in cottontop tamarins using the virus envelope glycoprotein gp340 produced from a bovine papillomavirus expression vector.
Finerty S; Tarlton J; Mackett M; Conway M; Arrand JR; Watkins PE; Morgan AJ
J Gen Virol; 1992 Feb; 73 ( Pt 2)():449-53. PubMed ID: 1311367
[TBL] [Abstract][Full Text] [Related]
4. Replication-defective recombinant adenovirus expressing the Epstein-Barr virus (EBV) envelope glycoprotein gp340/220 induces protective immunity against EBV-induced lymphomas in the cottontop tamarin.
Ragot T; Finerty S; Watkins PE; Perricaudet M; Morgan AJ
J Gen Virol; 1993 Mar; 74 ( Pt 3)():501-7. PubMed ID: 8383183
[TBL] [Abstract][Full Text] [Related]
5. Mapping of B-cell epitopes on the polypeptide chain of the Epstein-Barr virus major envelope glycoprotein and candidate vaccine molecule gp340.
Pither RJ; Zhang CX; Shiels C; Tarlton J; Finerty S; Morgan AJ
J Virol; 1992 Feb; 66(2):1246-51. PubMed ID: 1370550
[TBL] [Abstract][Full Text] [Related]
6. Immunization of cottontop tamarins and rabbits with a candidate vaccine against the Epstein-Barr virus based on the major viral envelope glycoprotein gp340 and alum.
Finerty S; Mackett M; Arrand JR; Watkins PE; Tarlton J; Morgan AJ
Vaccine; 1994 Oct; 12(13):1180-4. PubMed ID: 7839721
[TBL] [Abstract][Full Text] [Related]
7. Salivary and serum IgA antibodies to the Epstein-Barr virus glycoprotein gp340: incidence and potential for virus neutralization.
Yao QY; Rowe M; Morgan AJ; Sam CK; Prasad U; Dang H; Zeng Y; Rickinson AB
Int J Cancer; 1991 Apr; 48(1):45-50. PubMed ID: 1850382
[TBL] [Abstract][Full Text] [Related]
8. The Epstein-Barr virus (EBV) major envelope glycoprotein gp350/220-specific antibody reactivities in the sera of patients with different EBV-associated diseases.
Xu J; Ahmad A; Blagdon M; D'Addario M; Jones JF; Dolcetti R; Vaccher E; Prasad U; Menezes J
Int J Cancer; 1998 Oct; 79(5):481-6. PubMed ID: 9761116
[TBL] [Abstract][Full Text] [Related]
9. Persistent Epstein-Barr virus infection in the common marmoset (Callithrix jacchus).
Cox C; Chang S; Karran L; Griffin B; Wedderburn N
J Gen Virol; 1996 Jun; 77 ( Pt 6)():1173-80. PubMed ID: 8683204
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus vaccines.
Morgan AJ
Vaccine; 1992; 10(9):563-71. PubMed ID: 1323899
[TBL] [Abstract][Full Text] [Related]
11. Recombinant vaccinia virus expressing Epstein-Barr virus glycoprotein gp340 protects cottontop tamarins against EB virus-induced malignant lymphomas.
Morgan AJ; Mackett M; Finerty S; Arrand JR; Scullion FT; Epstein MA
J Med Virol; 1988 Jun; 25(2):189-95. PubMed ID: 2839612
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus-specific antibodies in Epstein-Barr virus-positive and -negative gastric carcinoma cases in Japan.
Shinkura R; Yamamoto N; Koriyama C; Shinmura Y; Eizuru Y; Tokunaga M
J Med Virol; 2000 Apr; 60(4):411-6. PubMed ID: 10686024
[TBL] [Abstract][Full Text] [Related]
13. Antibodies to LMP2A/2B in EBV-carrying malignancies.
Lennette ET; Winberg G; Yadav M; Enblad G; Klein G
Eur J Cancer; 1995 Oct; 31A(11):1875-8. PubMed ID: 8541116
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC).
Liu MT; Yeh CY
Radiat Med; 1998; 16(2):113-7. PubMed ID: 9650898
[TBL] [Abstract][Full Text] [Related]
15. High Epstein-Barr Virus Load and Genomic Diversity Are Associated with Generation of gp350-Specific Neutralizing Antibodies following Acute Infectious Mononucleosis.
Weiss ER; Alter G; Ogembo JG; Henderson JL; Tabak B; Bakiş Y; Somasundaran M; Garber M; Selin L; Luzuriaga K
J Virol; 2017 Jan; 91(1):. PubMed ID: 27733645
[TBL] [Abstract][Full Text] [Related]
16. Immune intervention against virus-associated human cancers.
Rickinson AB
Ann Oncol; 1995; 6 Suppl 1():69-71. PubMed ID: 8695548
[TBL] [Abstract][Full Text] [Related]
17. An animal model for acute and persistent Epstein-Barr virus infection.
Moghaddam A; Rosenzweig M; Lee-Parritz D; Annis B; Johnson RP; Wang F
Science; 1997 Jun; 276(5321):2030-3. PubMed ID: 9197263
[TBL] [Abstract][Full Text] [Related]
18. Elevated antibody titers to Epstein-Barr virus prior to the diagnosis of Epstein-Barr-virus-associated gastric adenocarcinoma.
Levine PH; Stemmermann G; Lennette ET; Hildesheim A; Shibata D; Nomura A
Int J Cancer; 1995 Mar; 60(5):642-4. PubMed ID: 7860138
[TBL] [Abstract][Full Text] [Related]
19. The Leeuwenhoek lecture, 1983. A prototype vaccine to prevent Epstein-Barr virus-associated tumours.
Epstein MA
Proc R Soc Lond B Biol Sci; 1984 Mar; 221(1222):1-20. PubMed ID: 6144103
[TBL] [Abstract][Full Text] [Related]
20. Establishment and characterization of a chronic infectious mononucleosislike syndrome in common marmosets.
Emini EA; Luka J; Armstrong ME; Banker FS; Provost PJ; Pearson GR
J Med Virol; 1986 Apr; 18(4):369-79. PubMed ID: 3011982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
